If you are interested in showcasing your company’s services to senior clinical development executives from Chinese and US BioPharmas, please contact: firstname.lastname@example.org.
PPC was established in 1997 and is a subsidiary of Novotech Health Holdings ("Novotech"). Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech Health Holdings is positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. As of August 31, 2021, NHH had a total of 2,075 FTEs working across our offices in 14 geographies in Asia-Pacific and the United States.
Redbud Medicine is a strategic CRO partner rooted in China and U.S., which are two important drug R&D markets in the world. By implementing artificial intelligent technology, Redbud optimizes every single process within clinical trial, and ultimately lower the operation cost and accelerate the clinical study process.
Redbud brings a nimble and stage-appropriate approach to clinical development. This ensures that activities are streamlined and resources conserved in early stages, while building a solid foundation for the greater complexity of later development stages.
Redbud team are practical and science-driven. The experienced team helps you avoid common development pitfalls. Ultimately Redbud relies on good science to make good decisions.
In terms of globalization, Redbud Medicine is at the forefront of the industry.
Jsure Health Technology
Shanghai Jsure Health Technology Co., Ltd. was established in 2008. Jsure Health is a provider of digital solutions for patients while adhering to a "patient-centered" philosophy. Jsureʼs business scope covers more than 40
different types of diseases. Additionally, Jsure Health has developed close relationships with 200+ sites and 5,000+ physicians. So far, Jsure Health has brought hope to 80,000+ patients, while over 50 new drugs have had accelerated approvals to be listed with Jsure Healthʼs efforts.
Linking the patients to hope and building new models for digital clinical research. Jsure is continuously promoting the development of healthcare.
The PPD clinical research business of Thermo Fisher Scientific is a leading global contract research organization, providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 28,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit thermofisher.com/ppd.
dMed-Clinipace is a global, full-service contract research organization (CRO) with the largest Asia-Pacific presence. Our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment, with an emphasis on personalized services and solutions, regulatory expertise, and therapeutic leadership. Our mission is to improve the way clinical research is performed in major therapeutic areas. We strive to impact the future of drug development and health care by combining the most advanced technology with the highest international clinical standards.
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading provider of innovative clinical research solutions across the full life cycle of biopharmaceutical and medical device products globally. With a broad portfolio of services and a promise of quality, from clinical development to commercialization, we are committed to moving our customers and patients through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 80 subsidiaries and 170 offices and sites, with over 8,000 employees across 46 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibility for the healthcare industry, embracing challenges to fulfill our commitment to serve unmet patients’ needs, and eventually saving lives.
ICON is the world’s leading clinical research organization, powered by healthcare intelligence. From molecule to medicine, we advance clinical
research providing outsourced development and commercialization services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 39,300 employees in 138 locations in 53 countries as 2022.
For further information about ICON, visit: www.iconplc.com.
Sanofi is a leading global biopharmaceutical company focused on human health. In 1982, Sanofi opened an office in China as one of the first multinational corporations to support China’s opening up and reform. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. We have 12 offices, 3 production sites, 4 R&D sites and 1 digital innovation hub in China. Sanofi is committed to introducing innovative medicines and vaccines faster in China, and leading digital innovations to serve the broadest base of the Chinese people.